Seven concepts that define Alex Zhavoronkov's scientific and public work.
Post-healthspan metric proposed by Zhavoronkov in 2026: the duration of peak productive, cognitive, and physical capacity — not merely 'years without disease.' Argues healthspan is too low a bar for longevity science and that we should instead aim for extended peak human performance.
The thesis that generative AI combined with large biomedical datasets, automated experimentation, and clinical-trial simulation will eventually achieve superhuman performance across the entire drug discovery and development pipeline — target identification, molecular design, trial design, and patient selection.
An AI-integrated biotechnology hub concept: a purpose-built ecosystem where residential, clinical, commercial, and research facilities are co-located and orchestrated by a central AI operating system. Continuous real-world health data feeds federated drug discovery models; clinical trials are embedded in daily life.
A public commitment to dedicate 100% of one's professional time and resources to extending healthy human lifespan through science, technology, and ethical advocacy. Founded by Zhavoronkov; signed by leading longevity researchers, investors, and executives.
Deep-learning biomarkers of biological age trained on transcriptomic, proteomic, methylation, and blood-test data. Pioneered by Zhavoronkov's group starting 2016 — first deep-learning hematological aging clock (PLOS ONE, 2016). Now a core tool in aging intervention research.
Alex Zhavoronkov coined both terms — 'generative chemistry' and 'generative biology' — to describe the use of deep generative models for de novo molecular design and biological target discovery. His group pioneered GANs for molecular generation (druGAN, ORGAN, 2016–2018), culminating in the 2019 GENTRL paper (Nature Biotechnology) — the first AI-designed DDR1 kinase inhibitor, generated and validated in just 21 days. These concepts became the foundation of modern AI-native drug discovery.
Alex Zhavoronkov coined the term 'longevity medicine' to describe an emerging medical specialty focused on extending healthy productive lifespan using AI-powered diagnostics, aging biomarkers, and targeted interventions. Unlike traditional geriatrics, longevity medicine is proactive — using deep aging clocks and multi-omics profiling to detect and reverse biological aging before disease manifests. The field now has dedicated practitioners, conferences, and academic programs worldwide.